Vendor review
Xian Yihang Technology reviews
Xian Yihang Technology reviews from 80 independent lab tests (Tirzepatide, Retatrutide and GHK-Cu): grade A, purity and fill accuracy. Is Xian Yihang Technology legit? See what its vials showed.
What the lab tests show
80 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Jul 13, 2026 | Semaglutide | 99.9 % | 14.1 mg of 10 mg (41 %) | Pass | View |
| Jul 9, 2026 | Retatrutide | 99.9 % | 64 mg of 60 mg (7 %) | Pass | View |
| Jun 24, 2026 | BPC-157 | 99.6 % | 4.54 mg of 5 mg (-9 %) | Pass | View |
| Jun 22, 2026 | Tirzepatide | 99.9 % | 28.6 mg of 30 mg (-5 %) | Pass | View |
| Jun 8, 2026 | Tirzepatide | 99.8 % | 126.3 mg of 120 mg (5 %) | Pass | View |
| Jun 1, 2026 | Tirzepatide | 99.9 % | 143.8 mg of 120 mg (20 %) | Pass | View |
| Jun 1, 2026 | Tirzepatide | 99.9 % | 37.2 mg of 30 mg (24 %) | Pass | View |
| Apr 23, 2026 | Retatrutide | 99.9 % | 31.4 mg of 30 mg (5 %) | Pass | View |
| Apr 23, 2026 | Retatrutide | 98.7 % | 30 mg of 30 mg (0 %) | Pass | View |
| Apr 23, 2026 | Retatrutide | 99.9 % | 20 mg of 20 mg (0 %) | Pass | View |
| Apr 23, 2026 | Retatrutide | 99.9 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Apr 23, 2026 | Tirzepatide | 99.9 % | 9.79 mg of 10 mg (-2 %) | Pass | View |
| Apr 23, 2026 | Tirzepatide | 99.9 % | 20.1 mg of 20 mg (1 %) | Pass | View |
| Apr 2, 2026 | Tirzepatide | 99.9 % | 67.7 mg of 60 mg (13 %) | Pass | View |
| Mar 21, 2026 | Ipamorelin | 99 % | 3.11 mg of 5 mg (-38 %) | Pass | View |
| Mar 10, 2026 | BPC-157 | 99.9 % | 9.72 mg of 10 mg (-3 %) | Pass | View |
| Mar 10, 2026 | TB-500 | 99.9 % | 9.3 mg of 10 mg (-7 %) | Pass | View |
| Mar 7, 2026 | Tirzepatide | 99.9 % | 178.9 mg of 120 mg (49 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 84.2 % | 18.6 mg of 20 mg (-7 %) | Pass | View |
| Mar 6, 2026 | GHK-Cu | 100 mg | Fail | View | |
| Mar 5, 2026 | Tirzepatide | 99.7 % | 42 mg of 40 mg (5 %) | Pass | View |
| Mar 4, 2026 | Retatrutide | 99.4 % | 5.4 mg of 5 mg (8 %) | Pass | View |
| Mar 3, 2026 | Semaglutide | 98.99 % | 21.2 mg of 20 mg (6 %) | Pass | View |
| Mar 3, 2026 | Retatrutide | 99.9 % | 29.5 mg of 30 mg (-2 %) | Pass | View |
| Mar 3, 2026 | Semaglutide | 99.9 % | 31.5 mg of 30 mg (5 %) | Pass | View |
| Mar 3, 2026 | Retatrutide | 99.29 % | 21.2 mg of 20 mg (6 %) | Pass | View |
| Mar 2, 2026 | Retatrutide | 99.9 % | 24.7 mg of 30 mg (-18 %) | Pass | View |
| Mar 2, 2026 | Tesamorelin | 99.9 % | 10.5 mg of 10 mg (5 %) | Pass | View |
| Mar 1, 2026 | TB-500 | 99.6 % | 2.3 mg of 2 mg (15 %) | Pass | View |
| Feb 26, 2026 | Retatrutide | 99.9 % | 11.3 mg of 10 mg (13 %) | Pass | View |
| Feb 20, 2026 | Tirzepatide | 99.8 % | 15.9 mg of 5 mg (218 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 99.89 % | 31.9 mg of 30 mg (6 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 98.96 % | 66 mg of 60 mg (10 %) | Pass | View |
| Feb 13, 2026 | BPC-157 | 99.9 % | 9.87 mg of 10 mg (-1 %) | Pass | View |
| Feb 13, 2026 | GHK-Cu | 99.9 % | 103 mg of 100 mg (3 %) | Pass | View |
| Feb 13, 2026 | Tesamorelin | 99.9 % | 10.5 mg of 10 mg (5 %) | Pass | View |
| Feb 13, 2026 | Ipamorelin | 99.9 % | 10.5 mg of 10 mg (5 %) | Pass | View |
| Feb 9, 2026 | TB-500 | 98.54 % | 9.45 mg of 10 mg (-6 %) | Pass | View |
| Jan 26, 2026 | Tirzepatide | 99.8 % | 12.3 mg of 10 mg (23 %) | Pass | View |
| Jan 15, 2026 | Retatrutide | 99.6 % | 11.1 mg of 10 mg (11 %) | Pass | View |
| Jan 15, 2026 | Tirzepatide | 98.62 % | 39 mg of 50 mg (-22 %) | Pass | View |
| Jan 1, 2026 | Retatrutide | 99.6 % | 31.6 mg of 30 mg (5 %) | Pass | View |
| Jan 1, 2026 | Tirzepatide | 99.7 % | 21.4 mg of 20 mg (7 %) | Pass | View |
| Nov 25, 2025 | Retatrutide | 99.95 % | 20 mg of 19.98 mg (0 %) | Pass | View |
| Nov 25, 2025 | Tirzepatide | 99.95 % | 30 mg of 30 mg (0 %) | Pass | View |
| Nov 25, 2025 | GHK-Cu | 99.95 % | 124 mg of 50 mg (148 %) | Pass | View |
| Oct 23, 2025 | Retatrutide | 99.43 % | 4.37 mg of 5 mg (-13 %) | Pass | View |
| Oct 23, 2025 | Tesamorelin | 97.78 % | 1.54 mg of 5 mg (-69 %) | Pass | View |
| Oct 23, 2025 | Retatrutide | 99.29 % | 4.59 mg of 5 mg (-8 %) | Pass | View |
| Oct 23, 2025 | Tirzepatide | 99.95 % | 21.5 mg of 20 mg (8 %) | Pass | View |
| Oct 23, 2025 | TB-500 | 96.7 % | 10.1 mg of 10 mg (1 %) | Pass | View |
| Oct 23, 2025 | GHK-Cu | 99.95 % | 40.5 mg of 50 mg (-19 %) | Pass | View |
| Oct 23, 2025 | GHK-Cu | 99.95 % | 97.2 mg of 100 mg (-3 %) | Pass | View |
| Oct 23, 2025 | Tesamorelin | 99.95 % | 1.66 mg of 2 mg (-17 %) | Pass | View |
| Oct 23, 2025 | Ipamorelin | 99.3 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Oct 21, 2025 | Retatrutide | 99.6 % | 22.7 mg of 20 mg (14 %) | Pass | View |
| Oct 21, 2025 | BPC-157 | 99.8 % | 11 mg of 10 mg (10 %) | Pass | View |
| Oct 21, 2025 | Tirzepatide | 99.8 % | 34.7 mg of 30 mg (16 %) | Pass | View |
| Oct 21, 2025 | Tesamorelin | 98.862 % | 9.91 mg of 10 mg (-1 %) | Pass | View |
| Oct 13, 2025 | Retatrutide | 99.7 % | 11.7 mg of 10 mg (17 %) | Pass | View |
What Xian Yihang Technology sells
No current listings on record.
About Xian Yihang Technology
Finnrick has tested 80 samples from Xian Yihang Technology across 8 products.